Ovarian Cancer clinical trials in Maine

12 actively recruiting ovarian cancer trials at 14 sites across Maine.

Data from ClinicalTrials.gov · last refreshed 2026-04-20

Phase 3 Recruiting Academic/Other

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…

Sponsor: NRG Oncology

NCT ID: NCT05879926

Sites in Maine:

Harold Alfond Center for Cancer Care — Augusta, Maine
MaineHealth Waldo Hospital — Belfast, Maine
MaineHealth Maine Medical Center - Biddeford — Biddeford, Maine
Mid Coast Hospital — Brunswick, Maine
New England Cancer Specialists - Kennebunk — Kennebunk, Maine

View on ClinicalTrials.gov →

Phase 3 Recruiting Network

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it dev…

Sponsor: Children's Oncology Group

NCT ID: NCT03067181

Sites in Maine:

Eastern Maine Medical Center — Bangor, Maine
Lafayette Family Cancer Center-EMMC — Brewer, Maine
MaineHealth Maine Medical Center - Portland — Portland, Maine
Maine Children's Cancer Program — Scarborough, Maine
MaineHealth Maine Medical Center- Scarborough — Scarborough, Maine

View on ClinicalTrials.gov →

Phase 3 Recruiting Network

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part o…

Sponsor: Children's Oncology Group

NCT ID: NCT06513962

Sites in Maine:

Maine Children's Cancer Program — Scarborough, Maine
MaineHealth Maine Medical Center- Scarborough — Scarborough, Maine

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

This is a clinical study that has two parts. It is testing a potential new medicine called Sofetabart Mipitecan (LY4170156) for people with certain types of ovarian, peritoneal, and fallopian tube cancers. Part A looks at participants whos…

Sponsor: Eli Lilly and Company

NCT ID: NCT07213804

Sites in Maine:

Maine Medical Center - Scarborough Campus — Scarborough, Maine

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallo…

Sponsor: AbbVie

NCT ID: NCT05445778

Sites in Maine:

Maine Medical Center - Scarborough Campus /ID# 269555 — Scarborough, Maine

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer get…

Sponsor: Merck Sharp & Dohme LLC

NCT ID: NCT06824467

Sites in Maine:

Maine Medical Center Research Institute-MaineHealth/Maine Medical Partners - GynOnc ( Site 0008) — Scarborough, Maine

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05564377

Sites in Maine:

Harold Alfond Center for Cancer Care — Augusta, Maine
Lafayette Family Cancer Center-EMMC — Brewer, Maine
MaineHealth Maine Medical Center- Scarborough — Scarborough, Maine
MaineHealth Cancer Care and IV Therapy - South Portland — South Portland, Maine

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite tre…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05554328

Sites in Maine:

Harold Alfond Center for Cancer Care — Augusta, Maine
Lafayette Family Cancer Center-EMMC — Brewer, Maine
MaineHealth Maine Medical Center- Scarborough — Scarborough, Maine

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismatch repair system (dMMR) endometrial carcinoma that has come back after a period …

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05112601

Sites in Maine:

MaineHealth Maine Medical Center- Scarborough — Scarborough, Maine

View on ClinicalTrials.gov →

Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT05334069

Sites in Maine:

Harold Alfond Center for Cancer Care — Augusta, Maine
MaineHealth Waldo Hospital — Belfast, Maine
MaineHealth Maine Medical Center - Biddeford — Biddeford, Maine
Lafayette Family Cancer Center-EMMC — Brewer, Maine
MaineHealth Cancer Care and IV Therapy - Brunswick — Brunswick, Maine

View on ClinicalTrials.gov →

NA Recruiting Academic/Other

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves…

Sponsor: NRG Oncology

NCT ID: NCT04251052

Sites in Maine:

MaineHealth Maine Medical Center - Portland — Portland, Maine
MaineHealth Maine Medical Center- Scarborough — Scarborough, Maine

View on ClinicalTrials.gov →

Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.

NCT ID: NCT03452774

Sites in Maine:

Massive Bio SYNERGY-AI site — Scarborough, Maine

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20